A phase Ib trial of cabozantinib in combination with durvalumab (MEDI4736) in previously treated patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies (CAMILLA).

Anwaar Saeed,Devin C. Koestler,Stephen K. Williamson,Joaquina Baranda,Weijing Sun,Raed Moh'd Taiseer Al-Rajabi,Anup Kasi,Mazin Al Kasspooles,Dharmalingam Subramaniam,Shrikant Anant

A phase Ib trial of cabozantinib in combination with durvalumab (MEDI4736) in previously treated patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies (CAMILLA).

2019

Anwaar Saeed
Devin C. Koestler
Stephen K. Williamson
Joaquina Baranda
Weijing Sun
Raed Moh'd Taiseer Al-Rajabi
Anup Kasi
Mazin Al Kasspooles
Dharmalingam Subramaniam
Shrikant Anant

TPS56Background: GI malignancies including Gastric (GC), esophageal (EAC), colon (CRC), and hepatocellular carcinoma (HCC) remain a significant health problem in the US & globally. The current stan...

Keywords:

Gastroesophageal cancer
Oncology
Pathology
Internal medicine
Durvalumab
Medicine
Cabozantinib
Hepatocellular carcinoma
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations